PlasmaGen Biosciences, a Bengaluru-based biopharmaceutical company focused on blood plasma-derived therapeutics, has raised ₹150 crore led by ViNS Bioproducts. The round also saw participation from high-net-worth individuals, family offices, pharma entrepreneurs, and existing investors.
The startup is backed by Eight Road Ventures and secured the funding at a valuation of over ₹1,500 crore.
The fresh funds raised will be used to scale international operations, expand the product portfolio, and strengthen manufacturing and leadership capabilities.
PlasmaGen has raised over ₹600 crore in total funding to date.
Founded in 2010, PlasmaGen Biosciences focuses on producing and marketing plasma-derived therapies like Immunoglobulin, Albumin, and clotting factors to bridge India’s demand-supply gap for these critical medicines, operating a modern fractionation plant in Kolar, Karnataka, and serving neurology, hematology, and critical care, aiming for self-reliance in plasma products.
The company has identified distribution partners in key export markets and is advancing regulatory approvals to commence international operations. Domestically, PlasmaGen continues to strengthen its market presence with its portfolio of plasma-derived therapeutics addressing significant unmet medical needs. It is also expanding its services in India across hospitals and physicians through a cold-chain-backed distribution network.
The company operates a plasma fractionation facility in Kolar, Karnataka, which began commercial operations in 2024.
Vivek V Kamath, Chief Executive Officer of PlasmaGen Biosciences, said, “The past year has been transformational for PlasmaGen, marking a step change in the scale and reach of the company. This momentum has put us on an exponential growth trajectory. With a clear plan and the support of this financing, we are well-positioned to turn our ambition into enduring impact for patients and partners worldwide.”
Vinod Nahar, Founder and Executive Chairman of PlasmaGen Biosciences, said, “The support from our incoming and existing investors underscores their trust in PlasmaGen’s mission and capabilities. From the outset, our objective has been to create a world-class, India-based plasma biopharmaceutical platform that delivers consistent quality and meaningful patient impact. This investment further strengthens PlasmaGen’s position as a long-term partner to healthcare systems and patients, both in India and internationally.”
Khushboo Daga, CEO, VINS Bioproducts, said, “VINS Bio is proud to spearhead this investment, aligning our expertise in biologics with PlasmaGen’s vision to close India’s plasma therapy gap. Together, we’re building a stronger, more innovative biopharma ecosystem for critical care worldwide.”
Siddharth Daga, Managing Director, VINS Bioproducts, said, “As leaders in animal health and biologics, VINS Bio sees PlasmaGen as a perfect partner. This funding empowers their growth while amplifying our shared mission in life-saving plasma proteins and international markets.”
